Literature DB >> 32590888

Predicting survival in non-functional pancreatic neuroendocrine tumours.

Qing-Quan Tan1, Xing Wang1, Le Yang1, Yong-Hua Chen1, Chun-Lu Tan1, Neng-Wen Ke1, Xu-Bao Liu1.   

Abstract

BACKGROUND: Owing to the limited prevalence and heterogeneity, it is difficult to predict long-term survival of non-functional pancreatic neuroendocrine tumours (NF-PNETs).This study aimed to evaluate the factors predicting disease-specific survival (DSS) for well-differentiated NF-PNETs.
METHODS: Data were collected retrospectively from 256 patients with pancreatic neuroendocrine tumours who underwent surgical resection between January 2009 and December at our institution. Of these, 103 NF-PNETs (40%) were identified for analysis.
RESULTS: Of the 103 patients, 54 were male (52%) and the mean age was 52 years (range 21-75 years). Most patients (60/103, 58%) in our series were symptomatic. Seventeen patients (16%) died during follow-up, with a median period of 47 months. There were 88 patients with well-differentiated tumours and 10 of them (10/88, 11%) died of tumour progression. Median DSS after primary resection was 58.8 months (range 16-122 months). Multivariate analysis identified age >52 years (P = 0.038) and tumour grade G2 (P = 0.001) as statistically significant predictors of DSS. There was no association between gender, tumour size, symptoms, surgical procedure, severe complications, tumour location, tumour size, resection margin, positive lymph nodes and vascular invasion with DSS.
CONCLUSION: Tumour grade, age, presence of symptoms and distant metastasis were related to poor DSS of NF-PNETs. Age >52 years and tumour grade G2 might be independent predictors of poor DSS for patients with well-differentiated NF-PNETs.
© 2020 Royal Australasian College of Surgeons.

Entities:  

Keywords:  non-functional pancreatic neuroendocrine tumour; outcome; pancreas; pancreatic neuroendocrine tumour; predictor

Mesh:

Year:  2020        PMID: 32590888     DOI: 10.1111/ans.16072

Source DB:  PubMed          Journal:  ANZ J Surg        ISSN: 1445-1433            Impact factor:   1.872


  3 in total

1.  Development and Validation of a Novel Radiomics-Based Nomogram With Machine Learning to Preoperatively Predict Histologic Grade in Pancreatic Neuroendocrine Tumors.

Authors:  Xing Wang; Jia-Jun Qiu; Chun-Lu Tan; Yong-Hua Chen; Qing-Quan Tan; Shu-Jie Ren; Fan Yang; Wen-Qing Yao; Dan Cao; Neng-Wen Ke; Xu-Bao Liu
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244

2.  Prognostic Factors of Small Non-Functional Pancreatic Neuroendocrine Tumors and the Risk of Lymph Node Metastasis: A Population-Level Study.

Authors:  Qingquan Tan; Xing Wang; Yichen Li; Yingyi Liu; Xubao Liu; Nengwen Ke
Journal:  Front Endocrinol (Lausanne)       Date:  2022-07-06       Impact factor: 6.055

3.  Long-term outcome after resection and thermal hepatic ablation of pancreatic neuroendocrine tumour liver metastases.

Authors:  J Kjaer; P Stålberg; J Crona; S Welin; P Hellman; A Thornell; O Norlen
Journal:  BJS Open       Date:  2021-07-06
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.